Insights From the First 820 Patients From the Brazilian Multicenter Registry of Hereditary Angioedema: The Key Role of Genetic Testing and Targeted Therapies
The Journal of Allergy and Clinical Immunology: In Practice · 2025
DOI: 10.1016/j.jaip.2025.08.026 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift The Journal of Allergy and Clinical Immunology: In Practice, 2025. Verfasst von Mariana P L Ferriani und 59 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, Ribeirão Preto Medical School, University of São Paulo, Ribeirão Preto, SP, Brazil. Hauptthemen laut MEDLINE: Angioedemas, Hereditary. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 81 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: National Council for Scientific and Technological Development, State of Sao Paulo Research Foundation.
Abstract (Originalsprache)
BACKGROUND: Hereditary angioedema (HAE) is a rare autosomal dominant disorder with a prevalence of 1:50,000 individuals. Delayed diagnosis and deaths from asphyxia still occur. OBJECTIVE: To identify knowledge and management gaps regarding clinical, genetic, and therapeutic aspects of HAE in Brazil, aiming to improve patient care and outcomes. METHODS: A Brazilian multicenter HAE registry was established, with patients' data included by treating physicians using the REDCap (Research Electronic Data Capture) platform. RESULTS: Of the 820 patients with HAE enrolled, 68.8% were female. Most (72.4%) experienced HAE due to C1 inhibitor deficiency (HAE-C1INH), whereas 19.4% had HAE with normal C1INH caused by variants in the F12 gene (HAE-FXII). Onset of symptoms occurred earlier in HAE-C1INH as compared with HAE-FXII (mean 11.2 years vs 19.4 years, respectively), and time for diagnosis was shorter in patients younger than 18 years, as compared with those 18 years and older (mean 1.8 years vs 14.5 years, respectively). Regarding treatment, 52.8% received first-line on-demand therapies (icatibant or plasma-derived C1INH [pdC1INH]). Only 4.8% used first-line options for long-term prophylaxis (LTP), such as lanadelumab or subcutaneous/intravenous pdC1INH. Attenuated androgens were used for LTP in 52% of patients, with adverse effects reported for 34.8%. CONCLUSIONS: Brazilian patients with HAE share common aspects with global patients, including predominance in women, and HAE-C1INH as the most common subtype. Available genetic testing allowed for identification of a notable proportion of HAE-FXII (19.4% of the patients). Despite recent advances, access to first-line therapies for LTP of HAE attacks remains limited.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Medicine, Ribeirão Preto Medical School, University of São Paulo, Ribeirão Preto, SP, Brazil.
- Department of Medicine, Ribeirão Preto Medical School, University of São Paulo, Ribeirão Preto, SP, Brazil. Electronic address: karla@fmrp.usp.br.
- Department of Medical Images, Hematology, and Oncology, Ribeirão Preto Medical School, University of São Paulo, Ribeirão Preto, SP, Brazil.
- Department of Pediatrics, Ribeirão Preto Medical School, University of São Paulo, Ribeirão Preto, SP, Brazil.
- Division of Allergy and Immunology, Escola Superior de Ciências da Santa Casa de Misericórdia de Vitória, Vitória, ES, Brazil.
- Division of Allergy and Immunology, Federal University of Paraná, Curitiba, PR, Brazil.
Förderung
- National Council for Scientific and Technological Development
- State of Sao Paulo Research Foundation
Zitieren
APA
Ferriani, M. P. L., Seneda Lemos, J. E., Arruda, L. K., Nunes, F. L., Dias, M. M., Kolarik, M. L., Roxo-Junior, P., Ferraro, M. F., Zanetti, M. E. T., Serpa, F. S., Chong-Neto, H. J., Minafra, F. G., Valle, S. O. R., Campos, R. A., da Silva, J., Mansour, E., Gonçalves, R. F., Toledo, E. C., Marcelino, F. C., …, & Grumach, A. S. (2025). Insights From the First 820 Patients From the Brazilian Multicenter Registry of Hereditary Angioedema: The Key Role of Genetic Testing and Targeted Therapies. The Journal of Allergy and Clinical Immunology: In Practice. https://doi.org/10.1016/j.jaip.2025.08.026
Vancouver
Ferriani MPL, Seneda Lemos JE, Arruda LK, Nunes FL, Dias MM, Kolarik ML, et al. Insights From the First 820 Patients From the Brazilian Multicenter Registry of Hereditary Angioedema: The Key Role of Genetic Testing and Targeted Therapies. The Journal of Allergy and Clinical Immunology: In Practice. 2025. doi:10.1016/j.jaip.2025.08.026
BibTeX
@article{Ferriani2025,
author = {Ferriani, Mariana P L and Seneda Lemos, José Eduardo and Arruda, L Karla and Nunes, Fernanda L and Dias, Marina M and Kolarik, Maitê L and Roxo-Junior, Persio and Ferraro, Maria Fernanda and Zanetti, Maria Eduarda T and Serpa, Faradiba S and Chong-Neto, Herberto J and Minafra, Fernanda G and Valle, Solange O R and Campos, Régis A and da Silva, Jane and Mansour, Eli and Gonçalves, Rozana F and Toledo, Eliana C and Marcelino, Fernanda C and Moreira, Iramirton F and Azoubel-Antunes, Adriana and Ferreira, Janaira F S and Dias, Gabriela A C and Aun, Marcelo V and Castro, Ana Paula B M and Oliva-Alonso, Maria L and Batigalia, Vanessa A and Tavares, Clarissa L T S V and Capelo, Albertina V and Moyses, Therezinha R and Rosário Filho, Nelson A and Jannuzzi, Lucca N P and Fragnan, Nyla T M L and Figueiredo, Joanemile P and Fonseca, Joice T and Teixeira, Ana Julia R and Nasser, Nayara M F and Ferraroni, Natasha R and Mendonça, Leonardo O and Iwashita, Márcia T and Prado, Alex I F and Tumelero, Melissa T and Machado, Julianne A and Kamoi, Tsukiyo O and Ferrel, Luciana M and Barbosa, Adriana M S C and de Moraes, Caroline G F B and Kruk, Tatielly and Figueiredo, Mariana R and Moraes, Maria Stela Y and Moreno, Adriana S and Maia, Luana S M and Traina, Fabiola and Ruy, Patricia C and Pesquero, João B and Bork, Konrad and Cichon, Sven and Aragon, Davi C and Giavina-Bianchi, Pedro and Grumach, Anete S},
title = {Insights From the First 820 Patients From the Brazilian Multicenter Registry of Hereditary Angioedema: The Key Role of Genetic Testing and Targeted Therapies},
journal = {The Journal of Allergy and Clinical Immunology: In Practice},
year = {2025},
doi = {10.1016/j.jaip.2025.08.026}
}
EUVIMED